Advances in Heart Failure - Is It Time to Redefine Patient Selection for Sodium-Glucose Co-transporter 2 Inhibitors?
Published: 09 October 2020
-
Views:
591
-
Likes:
7
-
Views:
591
-
Likes:
7
-
Up Next
-
15m 14s
-
9m 33sPart 1 SGLT2s as a Heart Failure Drug – How Did We Get Here? Martin R Cowie
-
10m 1sPart 2 Emerging Data SGLT2 Inhibitors in Heart Failure Faiez Zannad
-
11m 45sPart 3 Guidelines and Practice Implications Sanjay Kaul
Overview
This educational symposium was originally broadcast as part of the ESC 2020 Digital Congress.
The programme focuses on summarising recent data on SGLT2 inhibitors showing reductions in CV risk, HF hospitalisations and mortality, as well as improved quality-of-life. The expert panel also discuss how these agents should be introduced into clinical practice and contemporary heart failure guidelines for both diabetics and non-diabetics.
Learning Objectives
- Discuss Current SGLT2 Data and Guideline Recommendations for Utilization in Heart Failure
- Evaluate Emerging Data on the Treatment of Heart Failure with SGLT2 Inhibitors
- Understand the Implications of Emerging Data on the Treatment of Heart Failure With SGLT2 Inhibitors
More from this programme
Part 1
SGLT2s as a Heart Failure Drug – How Did We Get Here?
Part 2
Emerging Data SGLT2 Inhibitors in Heart Failure
Part 3
Guidelines and Practice Implications
Part 4
Q&A Discussion
| 1 session | |
| Q&A Discussion | Watch now |
Part 5
Follow-up Peer-to Peer Discussion
| 1 session | |
| Follow-up Peer-to Peer Discussion | Watch now |
Faculty Biographies
Martin R Cowie
Professor of Cardiology
Martin Cowie is Professor of Cardiology at King's College London, and Honorary Consultant Cardiologist at the Royal Brompton Hospital, London, UK. Prof Cowie chairs the Clinical Practice Committee of the British Cardiac Society and sits on the UK Department of Health’s Primary Care and Heart Failure Implementation Board.
Prof Cowie's research interests focus on health technology assessment and delivery of efficient and effective care for patients with heart failure, with a focus on diagnostics, drugs, and devices. He has had a longstanding interest in evaluating remote monitoring and other digital technologies in heart failure.
Prof Cowie’s studies and reviews have been published in a variety of peer-reviewed journals, including The Lancet, European Heart Journal, British Medical Journal, Heart and International Journal of Cardiology. He is a member of the editorial boards of Heart, The British Journal of Diabetes and…
Faiez Zannad
Professor of Therapeutics and Cardiology, Head of CIC
Prof Faiez Zannad is Professor of Therapeutics & Cardiology and Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU).
Prof Zannad is currently the Chairman of the ESC Working group on Pharmacology and Drug Therapy as well as a Boardmember of the ESC Heart Failure Association. He is Past-President of the French Society of Hypertension.
Prof Zannad is Co-Editor-in-Chief for Fundamental and Clinical Pharmacology, the official journal of the European Pharmacology Societies Federation (EUPHAR). He chairs and organises annual international meetings on CardioVascular Clinical Trials (CVCT) and on Biomarkers in Heart Failure.
Sanjay Kaul
Professor of Medicine
Dr Sanjay Kaul is a Cardiologist at the Cedars-Sinai Medical Center, US where he is also a Professor of Medicine. Dr Kaul received his medical training at the Government Medical College of the University of Kashmir in India.
Dr Kaul is a Fellow of the American Heart Association Councils on Circulation and Arteriosclerosis and Thrombosis, and a Fellow of the American College of Cardiology.
Dr Kaul’s clinical interests are in preventive cardiovascular medicine, diabetes, coronary artery disease. His research interests lie in the fields of acute coronary syndromes, clinical trial and statistical methodology and evidence-based medicine.